US 11,865,104 B2
Antitumor TET2 modulating compounds
Jaroslaw Maciejewski, Cleveland, OH (US); Babal K. Jha, Cleveland, OH (US); James G. Phillips, Cleveland, OH (US); Thomas Radivoyevitch, Cleveland, OH (US); Yihong Guan, Cleveland, OH (US); and Anand D. Tiwari, Cleveland, OH (US)
Assigned to THE CLEVELAND CLINIC FOUNDATION, Cleveland, OH (US)
Appl. No. 16/768,112
Filed by THE CLEVELAND CLINIC FOUNDATION, Cleveland, OH (US)
PCT Filed Nov. 29, 2018, PCT No. PCT/US2018/063069
§ 371(c)(1), (2) Date May 29, 2020,
PCT Pub. No. WO2019/108796, PCT Pub. Date Jun. 6, 2019.
Claims priority of provisional application 62/591,884, filed on Nov. 29, 2017.
Prior Publication US 2020/0306221 A1, Oct. 1, 2020
Int. Cl. A61K 31/366 (2006.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/366 (2013.01) [A61P 35/00 (2018.01); A61P 35/02 (2018.01)] 7 Claims
 
1. A method of treating cancer in a subject in need thereof by administering a therapeutically effective amount of a compound of Formula I:

OG Complex Work Unit Chemistry
wherein R1 and R2 are independently selected from CH3, CH2CH3, and C1-C6 alkyl, R3 is H and R4 is —CH3, or R3 and R4 are combined to form ═CH2 or a cyclopropyl group; and R5 and R6 are independently selected from H, halogen, —OH, —CF3, and C1-C6 alkyl, or R5 and R6 are combined to form ═O;
or a pharmaceutically acceptable salt thereof selected from the group of salts consisting of chloride, bromide, nitrate, ammonium, sulfate, tosylate, phosphate, tartrate, ethylenediamine, and maleate salts.